Latest filing published 25 Feb 2025 for Candel Therapeutics, Inc., €121k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Estuardo Aguilar-Cordova, listed as senior executive, appears in our data through filings on Candel Therapeutics, Inc. shares, published by SEC (Form 4). In total, 46 filings cover trades dated from 29 July 2021 to 21 February 2025.
The open-market record consists of 6 sales worth €443k, with no purchase. Outside the open market, there are 1 share grant and 1 option exercise.
On 25 February 2025 came the latest disclosure, a transaction for €121k in Candel Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations